Herpes zoster (HZ) is a blistering, dermatomal cutaneous eruption caused by the reactivation of varicella zoster virus. The incidence of HZ increases exponentially with age and is commonly seen in adults >60 years of age. Patients with psoriasis on biologic therapies have ≍2 times the risk of developing HZ compared with the general population. The approval of HZ vaccine by the US Food and Drug Administration in 2006 has significantly reduced the incidence of HZ and postherpetic neuralgia by 61.1% and 66.5%, respectively. However, this live vaccine is not currently recommended for immunocompromised patients, such as individuals with psoriasis on biologics. Two major concerns with live vaccinations in this patient population include the risk of impaired immunologic response and the increased incidence of HZ and its complications. However, recent evidence has shown that, despite these concerns, vaccinating patients with psoriasis on biologics with an HZ vaccine can be both safe and effective.
CarboneV., LeonardiA., PaveseM., RaviolaE., GiordanoM.Herpes zoster of the trigeminal nerve: a case report and review of the literature. Minerva Stomatol.2004; 53: 49–59.
2.
JavedS., JavedF., MaysR.M., TyringS.K.Herpes zoster vaccine awareness among people > 50 years of age and its implications on immunization. Dermatology Online J.2012; 18: 2.
StrangfeldA., ListingJ., HerzerP.Risk of herpes zoster in patients with rheumatoid arthritis treated with anti-TNF-alpha agents. JAMA.2009; 301: 737–44.
5.
FaillaV., JacquesJ., CastronovoC., NikkelsA.F.Herpes zoster in patients treated with biologicals. Dermatology.2012; 224: 251–6.
6.
DreiherJ., KreschF.S., ComaneshterD., CohenA.D.Risk of herpes zoster in patients with psoriasis treated with biologic drugs. JEADV.2012; 26: 1127–32.
7.
SmittenA.L., ChoiH.K., HochbergM.C.The risk of herpes zoster in patients with rheumatoid arthritis in the United States and the United Kingdom. Arthritis Rheum.2007; 57: 1431–8.
8.
WongG.H., GoeddelD.V.Tumor necrosis factors a and 13 inhibit virus replication and synergize with interferons. Nature.1986; 323: 819–22.
9.
FaillaV., CastronovoC., MeexC., NikkelsA.F.Protracted herpes zoster and severe postherpetic neuralgia after inadvertant infliximab administration. Eur J Dermatol.2011; 21: 782–3.
10.
Garcia-DovalI., Perez-ZafrillaB., DescalzoM.A.Incidence and risk of hospitalization due to shingles and chickenpox in patients with rheumatic disease treated with TNF antagonists. Ann Rheum Dis.2010; 69: 1751–5.
OsterG., HardingG., DukesE., EdelsbergJ., ClearyP.D.Pain, medication use, and health-related quality of life in older persons with postherpetic neuralgia: results from a population-based survey. J Pain.2005; 6: 356–63.
13.
BuccolieroG., LoneroG., RomanelliC., LoperfidoP., RestaF.Varicella zoster virus encephalitis during treatment with anti-tumor necrosis factor-alpha agent in a psoriatic arthritis patient. New Microbiol.2010; 33: 271–4.
14.
ManzanoV., RuizP., TorresM., GomezF.Severe pneumonia by acyclovir-resistant varicella-zoster virus during etanercept therapy. Rheumatology.2010; 49-1791-3.
OxmanM.N., LevinM.J., JohnsonG.R.A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N Engl J Med.2005; 352: 2271–84.
17.
LebwohlM., BagelJ., GelfandJ.From the Medical Board of the National Psoriasis Foundation: monitoring and vaccinations in patients treated with biologics for psoriasis. J Am Acad Dermatol.2008; 58: 94–105.
18.
RahierJ., MoutschenM., Van GompelA.Vaccinations in patients with immune-mediated inflammatory diseases. Rheumatology.2010; 49: 1815–27.
19.
MeaseP.J., RitchlinC.T., MartinR.W.Pneumococcal vaccine response in psoriatic arthritis patients during treatment with etanercept. J Rheumatol.2004; 31: 1356–61.
20.
KapetanovicM.C., RosemanC., GonssonG., TruedssonL., SaxneT., GeborekP.Antibody response is reduced following vacation with 7-valent conjugate pneumococcal vaccine in adult methotrexate-treated patients with established arthritis, but not those treated with tumor necrosis factor inhibitors. Arthritis Rheum.2011; 63: 3723–32.
21.
AgarwalN., OllingtonK., KaneshiroM.Frenck R, Melmed GY. Are immunosuppressive medications associated with decreased responses to routine immunizations? A systematic review. Vaccine.2012; 30: 1413–24.
22.
OxmanM.N.Zoster vaccine: current status and future prospects. Clin Infect Dis.2010; 51: 17–213.
23.
WeinbergA., LevinM.J., MacgregorR.R.Safety and immunogenicity of a live attenuated varicella vaccine in VZV-seropositive HIV infected adults. Hum Vaccin.2010; 6: 318–21.
24.
ZhangJ., DelzellE., XieF.The use, safety, and effectiveness of herpes zoster vaccination in individuals with inflammatory and autoimmune diseases: a longitudinal observational study. Arthritis Res Ther.2011; 13: R174.
25.
ZhangJ., XieF., DelzellE.Association between vaccination for herpes zoster and risk of herpes zoster infection among older patients with selected immune-mediated diseases. JAMA.2012; 308: 43–9.
